Nitric oxide as a marker for levo-thyroxine therapy in subclinical hypothyroid patients

Current Vascular Pharmacology

Volumn 14, Issue 3, 2016, Pages 266-270

  Obradovic, Milan ^a   Gluvic, Zoran ^b   Sudar Milovanovic, Emina ^a   Panic, Anastasija ^a   Trebaljevac, Jovana ^a   Bajic, Vladan ^a   Zarkovic, Milos ^b   Isenovic, Esma R ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Biomarkers; Cardiovascular disease; Lipids; Nitric oxide; Subclinical hypothyroidism; Thyroid stimulating hormone

Indexed keywords

LEVOTHYROXINE; NITRIC OXIDE; BIOLOGICAL MARKER; LIOTHYRONINE; THYROTROPIN; THYROXINE;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; ENDOTHELIAL DYSFUNCTION; GENE EXPRESSION; GOITER; HUMAN; HYPOTHYROIDISM; INFLAMMATION; OXIDATIVE STRESS; PREVALENCE; THYROTROPIN BLOOD LEVEL; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; CARDIOVASCULAR DISEASES; COMPLICATION; METABOLISM; RISK FACTOR;

ANIMALS; BIOMARKERS; CARDIOVASCULAR DISEASES; HUMANS; HYPOTHYROIDISM; NITRIC OXIDE; RISK FACTORS; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE;

EID: 84964061247     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161114666160208143537     Document Type: Article

References (88)

1. Xu C, Yang X, Liu W, et al. Thyroid stimulating hormone, independent of thyroid hormone, can elevate the serum total cholesterol level in patients with coronary heart disease: a crosssectional design. Nutr Metab (Lond) 2012; 9: 44.
2. Chakera AJ, Pearce SH, Vaidya B. Treatment for primary hypothyroidism: current approaches and future possibilities. Drug Des Devel Ther 2012; 6: 1-11.
3. Cooper DS. Clinical practice. Subclinical hypothyroidism. N Engl J Med 2001; 345: 260-5.
4. Ayala AR, Danese MD, Ladenson PW. When to treat mild hypothyroidism. Endocrinol Metab Clin North Am 2000; 29: 399-415.
5. Gharib H, Tuttle RM, Baskin HJ, et al. Consensus Statement #1: Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and The Endocrine Society. Thyroid 2005; 15: 24-8.
6. Staub JJ, Althaus BU, Engler H, et al. Spectrum of subclinical and overt hypothyroidism: effect on thyrotropin, prolactin, and thyroid reserve, and metabolic impact on peripheral target tissues. Am J Med 1992; 92: 631-42.
7. Lioudaki E, Mavroeidi NG, Mikhailidis DP, et al. Subclinical hypothyroidism and vascular risk: an update. Hormones (Athens) 2013; 12: 495-506.
8. Imaizumi M, Akahoshi M, Ichimaru S, et al. Risk for ischemic heart disease and all-cause mortality in subclinical hypothyroidism. J Clin Endocrinol Metab 2004; 89: 3365-70.
9. Surks MI, Ocampo E. Subclinical thyroid disease. Am J Med 1996; 100: 217-23.
10. Hak AE, Pols HA, Visser TJ, et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med 2000; 132: 270-8.
11. Gao CX, Yang B, Guo Q, et al. High thyroid-stimulating hormone level is associated with the risk of developing atherosclerosis in subclinical hypothyroidism. Horm Metab Res 2015; 47: 220-4.
12. Rodondi N, Newman AB, Vittinghoff E, et al. Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch Intern Med 2005; 165: 2460-6.
13. Walsh JP, Bremner AP, Bulsara MK, et al. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med 2005; 165: 2467-72.
14. Rodondi N, den Elzen WP, Bauer DC, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA 2010; 304: 1365-74.
15. Razvi S, Weaver JU, Vanderpump MP, et al. The incidence of ischemic heart disease and mortality in people with subclinical hypothyroidism: reanalysis of the Whickham Survey cohort. J Clin Endocrinol Metab 2010; 95: 1734-40.
16. Lu M, Yang CB, Gao L, et al. Mechanism of subclinical hypothyroidism accelerating endothelial dysfunction (Review). Exp Ther Med 2015; 9: 3-10.
17. Kumar A, Suresh DR, Annam V, et al. Significance of early biochemical markers of atherosclerosis in subclinical hypothyroidism patients with normal lipid profile. Int J Biol Med Res 2012; 3: 2483-6.
18. Kvetny J, Heldgaard PE, Bladbjerg EM, et al. Subclinical hypothyroidism is associated with a low-grade inflammation, increased triglyceride levels and predicts cardiovascular disease in males below 50 years. Clin Endocrinol (Oxf) 2004; 61: 232-8.
19. Turemen EE, Cetinarslan B, Sahin T, et al. Endothelial dysfunction and low grade chronic inflammation in subclinical hypothyroidism due to autoimmune thyroiditis. Endocr J 2011; 58: 349-54.
20. Cebeci E, Alibaz-Oner F, Usta M, et al. Evaluation of oxidative stress, the activities of paraoxonase and arylesterase in patients with subclinical hypothyroidism. J Investig Med 2012; 60: 23-8.
21. Makino A, Kamata K. Possible modulation by endothelin-1, nitric oxide, prostaglandin I2 and thromboxane A2 of vasoconstriction induced by an alpha-agonist in mesenteric arterial bed from diabetic rats. Diabetologia 1998; 41: 1410-8.
22. Dardano A, Ghiadoni L, Plantinga Y, et al. Recombinant human thyrotropin reduces endothelium-dependent vasodilation in patients monitored for differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006; 91: 4175-8.
23. Won CM. Kinetics of degradation of levothyroxine in aqueous solution and in solid state. Pharm Res 1992; 9: 131-7.
24. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004; 291: 228-38.
25. Roberts CG, Ladenson PW. Hypothyroidism. Lancet 2004; 363: 793-803.
26. Cooper DS. Subclinical thyroid disease: consensus or conundrum? Clin Endocrinol (Oxf) 2004; 60: 410-2.
27. Esper RJ, Nordaby RA, Vilarino JO, et al. Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol 2006; 5: 4.
28. Ito A, Tsao PS, Adimoolam S, et al. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999; 99: 3092-5.
29. Ozcan O, Cakir E, Yaman H, et al. The effects of thyroxine replacement on the levels of serum asymmetric dimethylarginine (ADMA) and other biochemical cardiovascular risk markers in patients with subclinical hypothyroidism. Clin Endocrinol (Oxf) 2005; 63: 203-6.
30. Taddei S, Caraccio N, Virdis A, et al. Low-grade systemic inflammation causes endothelial dysfunction in patients with Hashimoto's thyroiditis. J Clin Endocrinol Metab 2006; 91: 5076-82.
31. Whetsell M, Bagriacik EU, Seetharamaiah GS, et al. Neuroendocrine-induced synthesis of bone marrow-derived cytokines with inflammatory immunomodulating properties. Cell Immunol 1999; 192: 159-66.
32. Gao X, Xu X, Belmadani S, et al. TNF-alpha contributes to endothelial dysfunction by upregulating arginase in ischemia/ reperfusion injury. Arterioscler Thromb Vasc Biol 2007; 27: 1269-75.
33. Schwartz R, Osborne-Lawrence S, Hahner L, et al. C-reactive protein downregulates endothelial NO synthase and attenuates reendothelialization in vivo in mice. Circ Res 2007; 100: 1452-9.
34. Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of Creactive protein. Circulation 2002; 105: 1890-6.
35. Balzan S, Del Carratore R, Nicolini G, et al. Proangiogenic effect of TSH in human microvascular endothelial cells through its membrane receptor. J Clin Endocrinol Metab 2012; 97: 1763-70.
36. Tian L, Zhang L, Liu J, et al. Effects of TSH on the function of human umbilical vein endothelial cells. J Mol Endocrinol 2014; 52: 215-22.
37. Sarati LI, Martinez CR, Artes N, et al. Hypothyroidism: age-related influence on cardiovascular nitric oxide system in rats. Metabolism 2012; 61: 1301-11.
38. Cooper DS, Biondi B. Subclinical thyroid disease. Lancet 2012; 379: 1142-54.
39. Turner HE, Wass JAH. Oxford handbook of endocrinology and diabetes, 2nd ed. Oxford University Press: Oxford; New York 2009; pp. xliii, 902 p.
40. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev 2008; 29: 76-131.
41. Biondi B. Thyroid and obesity: an intriguing relationship. J Clin Endocrinol Metab 2010; 95: 3614-7.
42. Surks MI, Hollowell JG. Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol Metab 2007; 92: 4575-82.
43. Sawin CT, Castelli WP, Hershman JM, et al. The aging thyroid. Thyroid deficiency in the Framingham Study. Arch Intern Med 1985; 145: 1386-8.
44. Canaris GJ, Manowitz NR, Mayor G, et al. The Colorado thyroid disease prevalence study. Arch Intern Med 2000; 160: 526-34.
45. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87: 489-99.
46. Helfand M, Force USPST. Screening for subclinical thyroid dysfunction in nonpregnant adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2004; 140: 128-41.
47. Tunbridge WM, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) 1977; 7: 481-93.
48. Nystrom E, Bengtsson C, Lindquist O, et al. Thyroid disease and high concentration of serum thyrotrophin in a population sample of women. A 4-year follow-up. Acta Med Scand 1981; 210: 39-46.
49. Fazio S, Palmieri EA, Lombardi G, et al. Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res 2004; 59: 31-50.
50. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001; 344: 501-9.
51. Kahaly GJ, Dillmann WH. Thyroid hormone action in the heart. Endocr Rev 2005; 26: 704-28.
52. Davis PJ, Davis FB. Nongenomic actions of thyroid hormone on the heart. Thyroid 2002; 12: 459-66.
53. Danzi S, Klein I. Thyroid hormone and blood pressure regulation. Curr Hypertens Rep 2003; 5: 513-20.
54. Tieche M, Lupi GA, Gutzwiller F, et al. Borderline low thyroid function and thyroid autoimmunity. Risk factors for coronary heart disease? Br Heart J 1981; 46: 202-6.
55. Bastenie PA, Vanhaelst L, Bonnyns M, et al. Preclinical hypothyroidism: a risk factor for coronary heart-disease. Lancet 1971; 1: 203-4.
56. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23: 168-75.
57. Gluvic Z, Sudar E, Tica J, et al. Effects of levothyroxine replacement therapy on parameters of metabolic syndrome and atherosclerosis in hypothyroid patients: a prospective pilot study. Int J Endocrinol 2015; 2015: 147070.
58. Asvold BO, Vatten LJ, Nilsen TI, et al. The association between TSH within the reference range and serum lipid concentrations in a population-based study. The HUNT Study. Eur J Endocrinol 2007; 156: 181-6.
59. Xiang GD, Xiang LW, He HL, et al. Postprandial lipaemia suppresses endothelium-dependent arterial dilation in patients with hypothyroidism. Endocrine 2012; 42: 391-8.
60. Lai Y, Wang J, Jiang F, et al. The relationship between serum thyrotropin and components of metabolic syndrome. Endocr J 2011; 58: 23-30.
61. Rodondi N, den Elzen WP, Bauer DC, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA 2010; 304: 1365-74.
62. Dean JW, Fowler PB. Exaggerated responsiveness to thyrotrophin releasing hormone: a risk factor in women with coronary artery disease. Br Med J (Clin Res Ed) 1985; 290: 1555-61.
63. Heinonen OP, Gordin A, Aho K, et al. Symptomless autoimmune thyroiditis in coronary heart-disease. Lancet 1972; 1: 785-6.
64. Cooper DS, Halpern R, Wood LC, et al. L-Thyroxine therapy in subclinical hypothyroidism. A double-blind, placebo-controlled trial. Ann Intern Med 1984; 101: 18-24.
65. Vanderpump MP, Tunbridge WM, French JM, et al. The development of ischemic heart disease in relation to autoimmune thyroid disease in a 20-year follow-up study of an English community. Thyroid 1996; 6: 155-60.
66. O'Kane MJ, Neely RD, Trimble ER, et al. The incidence of asymptomatic hypothyroidism in new referrals to a hospital lipid clinic. Ann Clin Biochem 1991; 28 (Pt 5): 509-11.
67. Alaghband-Zadeh J, Carter GD, Daly JR, et al. Association between exaggerated responsiveness to thyrotrophin-releasing hormone and hypercholesterolaemia. Lancet 1977; 2: 998-1000.
68. Ball MJ, Griffiths D, Thorogood M. Asymptomatic hypothyroidism and hypercholesterolaemia. J R Soc Med 1991; 84: 527-9.
69. Bastenie PA, Vanhaelst L, Golstein J, et al. Asymptomatic autoimmune thyroiditis and coronary heart-disease. Cross-sectional and prospective studies. Lancet 1977; 2: 155-8.
70. Murad F. Cyclic guanosine monophosphate as a mediator of vasodilation. J Clin Invest 1986; 78: 1-5.
71. McAllister RM, Albarracin I, Price EM, et al. Thyroid status and nitric oxide in rat arterial vessels. J Endocrinol 2005; 185: 111-9.
72. Uribe RM, Cisneros M, Vargas MA, et al. The systemic inhibition of nitric oxide production rapidly regulates TRH mRNA concentration in the paraventricular nucleus of the hypothalamus and serum TSH concentration. Studies in control and cold-stressed rats. Brain Res 2011; 1367: 188-97.
73. Arikan E, Karadag CH, Guldiken S. Asymmetric dimethylarginine levels in thyroid diseases. J Endocrinol Invest 2007; 30: 186-91.
74. Vicinanza R, Coppotelli G, Malacrino C, et al. Oxidized lowdensity lipoproteins impair endothelial function by inhibiting nongenomic action of thyroid hormone-mediated nitric oxide production in human endothelial cells. Thyroid 2013; 23: 231-8.
75. Vargas F, Fernandez-Rivas A, Osuna A. Effects of methimazole in the early and established phases of NG-nitro-L-arginine methyl ester hypertension. Eur J Endocrinol 1996; 135: 506-13.
76. Vargas F, Moreno JM, Wangensteen R, et al. The endocrine system in chronic nitric oxide deficiency. Eur J Endocrinol 2007; 156: 1-12.
77. Vargas F, Moreno JM, Rodriguez-Gomez I, et al. Vascular and renal function in experimental thyroid disorders. Eur J Endocrinol 2006; 154: 197-212.
78. Xiao Z, Zhang Z, Ranjan V, et al. Shear stress induction of the endothelial nitric oxide synthase gene is calcium-dependent but not calcium-activated. J Cell Physiol 1997; 171: 205-11.
79. Noris M, Morigi M, Donadelli R, et al. Nitric oxide synthesis by cultured endothelial cells is modulated by flow conditions. Circ Res 1995; 76: 536-43.
80. Klein I. Thyroid hormone and the cardiovascular system. Am J Med 1990; 88: 631-7.
81. Delp MD, McAllister RM, Laughlin MH. Exercise training alters aortic vascular reactivity in hypothyroid rats. Am J Physiol 1995; 268: H1428-35.
82. Moreno JM, Wangensteen R, Sainz J, et al. Role of endotheliumderived relaxing factors in the renal response to vasoactive agents in hypothyroid rats. Am J Physiol Endocrinol Metab 2003; 285: E182-8.
83. Vargas F, Fernandez-Rivas A, Garcia Estan J, et al. Endotheliumdependent and endothelium-independent vasodilation in hyperthyroid and hypothyroid rats. Pharmacology 1995; 51: 308-14.
84. McAllister RM, Luther KL, Pfeifer PC. Thyroid status and response to endothelin-1 in rat arterial vessels. Am J Physiol Endocrinol Metab 2000; 279: E252-8.
85. Razvi S, Ingoe L, Keeka G, et al. The beneficial effect of Lthyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. J Clin Endocrinol Metab 2007; 92: 1715-23.
86. Cabral MD, Teixeira P, Soares D, et al. Effects of thyroxine replacement on endothelial function and carotid artery intimamedia thickness in female patients with mild subclinical hypothyroidism. Clinics (Sao Paulo) 2011; 66: 1321-8.
87. Grieve DJ, Fletcher S, Pitsillides AA, et al. Effects of oral propylthiouracil treatment on nitric oxide production in rat aorta. Br J Pharmacol 1999; 127: 1-8.
88. Vargas F, Osuna A, Fernandez-Rivas A. Vascular reactivity and flow-pressure curve in isolated kidneys from rats with N-nitro-Larginine methyl ester-induced hypertension. J Hypertens 1996; 14: 373-9.